Druart Charlotte, El Sankari Souraya, van Pesch Vincent
Neurology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Patient Relat Outcome Meas. 2017 Dec 21;9:1-10. doi: 10.2147/PROM.S122401. eCollection 2018.
With a growing number of disease-modifying therapies becoming available for relapsing multiple sclerosis, there is an important need to gather real-world evidence data regarding long-term treatment effectiveness and safety in unselected patient populations. Although not providing as high a level of evidence as randomized controlled trials, and prone to bias, real-world studies from observational studies or registries nevertheless provide crucial information on real-world outcomes of a given therapy. In addition, evaluation of treatment satisfaction and impact on quality of life are increasingly regarded as complementary outcome measures. Fingolimod was the first oral disease-modifying therapy approved for relapsing multiple sclerosis. This review aims to summarize current knowledge on the long-term effectiveness and safety outcomes of multiple sclerosis patients on fingolimod. Impact on treatment satisfaction and quality of life will be discussed according to available data.
随着越来越多的疾病修正疗法可用于复发型多发性硬化症，迫切需要收集关于未选择患者群体长期治疗有效性和安全性的真实世界证据数据。尽管真实世界研究不像随机对照试验那样提供高水平的证据，且容易产生偏差，但来自观察性研究或登记处的真实世界研究仍能提供关于特定疗法真实世界疗效的关键信息。此外，对治疗满意度和生活质量影响的评估越来越被视为补充性结局指标。芬戈莫德是首个被批准用于复发型多发性硬化症的口服疾病修正疗法。本综述旨在总结目前关于接受芬戈莫德治疗的多发性硬化症患者长期有效性和安全性结局的知识。将根据现有数据讨论对治疗满意度和生活质量的影响。
